<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03461627</url>
  </required_header>
  <id_info>
    <org_study_id>SMTLTKS-CS-01</org_study_id>
    <nct_id>NCT03461627</nct_id>
  </id_info>
  <brief_title>Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma</brief_title>
  <official_title>Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma: A Randomized, Double-blind, Double-dummy, Positive-controlled, Parallel-group Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      assess the efficacy and safety of Salmeterol Xinafoate and Fluticasone Propinate Powder for
      inhalation (50ug/250ug) in combination with seretide to patients with Asthma.

      a randomized, double-blind, double-dummy, positive-controlled, parallel-group trail.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Drug：Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) Drug：Seretide (50ug/250ug)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline (visit 2) in Forced expiratory volume in 1 second (FEV1) on day 28</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (visit 2) in Forced vital capacity (FVC) on day 28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1~AUC0-12h</measure>
    <time_frame>12 hours</time_frame>
    <description>The Forced expiratory volume in 1 second of area under the curve from 0h to 12h on day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF</measure>
    <time_frame>28 days</time_frame>
    <description>The mean of morning and night peak expiratory flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean of morning and night Asthma symptom scores</measure>
    <time_frame>up to 28 days</time_frame>
    <description>the outcomes are respectively: Day-1~day-7,Day1~day7,Day8~day14,Day15~day21,Day22~day28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean of peak expiratory flow (PEF)variation of morning and night</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of ventolin during the treatment</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of asthma acute exacerbations with subjects</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject self- questionare at visit 4</measure>
    <time_frame>28 days</time_frame>
    <description>questionare respectively have significant effectiveness , effectiveness ,Invalid , Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire of Asthma control test scores</measure>
    <time_frame>28 days</time_frame>
    <description>25 score reprent Partially controlled；20-25 score represent fully controlled;&lt;20 score represent not controlled</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Salmeterol Xinafoate and Fluticasone Propinate Powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) 50ug/250ug 1 puff twice a day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seretide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50ug/250ug 1 puff twice a day for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol Xinafoate and Fluticasone Propinate Powder</intervention_name>
    <description>50ug/250ug 1 puff twice a day for 4 weeks</description>
    <arm_group_label>Salmeterol Xinafoate and Fluticasone Propinate Powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide</intervention_name>
    <description>50ug/250ug 1 puff twice a day for 4 weeks</description>
    <arm_group_label>Seretide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with asthma diagnosed according to the Global INitiative for Asthma (GINA)
             criteria.

               -  Inadequate asthma control on an inhaled corticosteroids alone at a dose of ≤ 800
                  μg/day of budesonide, ≤ 1000μg/day of Beclomethasone; ≤ 500 μg/day of fluticasone

               -  Inadequate asthma control on bronchodilators

               -  Inadequate asthma control on an ICS (medium and low dose)-LABA combination

               -  primarily diagnosed with asthma

          -  Positive bronchodilation test [an increase in of FEV1﹥200 ml and the FEV1 change﹥12%
             from the baseline] or PEF variation﹥20%

          -  Age between 18-70 years

          -  Patients should participate in the study voluntarily and sign informed consent;

          -  Female patients can participate if they are surgically sterile or completed menopause
             or females capable of having children and agree not to attempt pregnancy while
             receiving study therapy; Male patients can participate if they are surgically sterile
             or males capable of having children and agree not to attempt pregnancy while receiving
             study therapy.

        Exclusion Criteria:

          -  Allergic to salmeterol, fluticasone propionate or to ventolin.

          -  Have a current diagnosis of chronic obstructive pulmonary disease (COPD), pneumonia,
             pneumothorax, atelectasis, pulmonary fibrosis, bronchopulmonary dysplasia, chronic
             bronchitis or other respiratory tract disorders (not including asthma).

          -  Any respiratory tract infection, sinus infection or eardrum infection within 4 weeks
             prior to the screening .visit

          -  History or severe cardiovascular disease or hematopoietic system disease (congestive
             heart failure, clinically relevant coronary heart disease, apoplexy, clinically
             relevant cardiac arrhythmias, aortic aneurysm, and uncontrolled hypertension (systolic
             blood pressure above 160mmHg or diastolic blood pressure above 100 mmHg continuously
             measured more than twice.))

          -  Patients treated with leukotriene antagonist, such as zafirlukast, pranlukast, and
             montelukast.

          -  Expected medication to improve asthma other than ventolin

          -  Subjects who suffer from serious, uncontrolled diseases (including psychological
             disorders), in researcher's opinion, under great risks.

          -  Hepatic dysfunction: aspartate amino transferase (AST) and alanine amino transferase
             (ALT) levels of &gt; 2.0 × ULN; renal dysfunction: serum creatinine level of &gt; ULN )

          -  A history of both HBV infection and HCV infection.

          -  In Human Immunodeficiency Virus (HIV)-positive status

          -  Subjects with uncontrolled diabetics or fasting glucose &gt; 10mmol/L

          -  Use of any β-blocking agent, including eye-drops

          -  In oral glucocorticoid medication or a history of systemic corticosteroid medication
             within 30 days of the screening visit

          -  Subjects who participated in other clinical studies within 2 months

          -  Subjects who have previously enrolled into this study

          -  Pregnancy, breast-feeding or planned pregnancy during the study

          -  Researchers think that do not fit into the group.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>jinping zheng, doctor</last_name>
    <phone>020-83062869</phone>
    <email>18928868238@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinfeng Feng, doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>randomized</keyword>
  <keyword>double-blind</keyword>
  <keyword>double-dummy</keyword>
  <keyword>positive-controlled</keyword>
  <keyword>parallel-group</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

